{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:03:49Z","timestamp":1793232229741,"version":"4.5.0"},"reference-count":224,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G08818N"],"award-info":[{"award-number":["G08818N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bcp.2022.115322","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T11:14:54Z","timestamp":1666782894000},"page":"115322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":137,"special_numbering":"C","title":["Acyclovir resistance in herpes simplex viruses: Prevalence and therapeutic alternatives"],"prefix":"10.1016","volume":"206","author":[{"given":"Hanna H.","family":"Schalkwijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Snoeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Andrei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1023\/A:1007905910939","article-title":"Genomic organization and evolution of the human herpesviruses","volume":"16","author":"Weir","year":"1998","journal-title":"Virus Genes"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2022.115322_b0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0378-1135(01)00492-8","article-title":"Evolution of the herpesviruses","volume":"86","author":"Davison","year":"2002","journal-title":"Vet. Microbiol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00705-008-0278-4","article-title":"The order Herpesvirales","volume":"154","author":"Davison","year":"2009","journal-title":"Arch. Virol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115322_b0020","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2141.2011.08988.x","article-title":"Management of multidrug-resistant viruses in the immunocompromised host","volume":"156","author":"Sellar","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2011.03.003","article-title":"Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients","volume":"305","author":"Cesarman","year":"2011","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.bcp.2022.115322_b0030","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1172\/JCI136225","article-title":"Herpesvirus latency","volume":"130","author":"Cohen","year":"2020","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.antiviral.2009.04.010","article-title":"Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection","volume":"83","author":"James","year":"2009","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.bcp.2022.115322_b0040","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.19.237149","article-title":"Herpes simplex virus: global infection prevalence and incidence estimates, 2016","volume":"98","author":"James","year":"2020","journal-title":"Bull. World Health Organ."},{"issue":"10","key":"10.1016\/j.bcp.2022.115322_b0045","doi-asserted-by":"crossref","first-page":"e0140765","DOI":"10.1371\/journal.pone.0140765","article-title":"Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0050","doi-asserted-by":"crossref","first-page":"e114989","DOI":"10.1371\/journal.pone.0114989","article-title":"Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0055","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jri.2010.12.004","article-title":"Increased prevalence of sexually transmitted viral infections in women: the role of female sex hormones in regulating susceptibility and immune responses","volume":"88","author":"Kaushic","year":"2011","journal-title":"J. Reprod. Immunol."},{"issue":"9267","key":"10.1016\/j.bcp.2022.115322_b0060","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","article-title":"Herpes simplex virus infections","volume":"357","author":"Whitley","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0065","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ajo.2005.10.008","article-title":"Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy","volume":"141","author":"Pepose","year":"2006","journal-title":"Am. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.bcp.2022.115322_b0070","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/01.OLQ.0000092387.58746.C7","article-title":"Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students","volume":"30","author":"Roberts","year":"2003","journal-title":"Sex. Transm. Dis."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/sextrans-2018-053830","article-title":"Increasing proportion of herpes simplex virus type 1 among women and men diagnosed with first-episode anogenital herpes: a retrospective observational study over 14 years in Melbourne","volume":"95","author":"Durukan","year":"2019","journal-title":"Australia, Sex Transm Infect"},{"issue":"8","key":"10.1016\/j.bcp.2022.115322_b0080","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jama.296.8.964","article-title":"Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States","volume":"296","author":"Xu","year":"2006","journal-title":"JAMA"},{"issue":"9907","key":"10.1016\/j.bcp.2022.115322_b0085","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(13)62035-8","article-title":"Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal)","volume":"382","author":"Mercer","year":"2013","journal-title":"Lancet"},{"issue":"9605","key":"10.1016\/j.bcp.2022.115322_b0090","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(07)61908-4","article-title":"Genital herpes","volume":"370","author":"Gupta","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0095","doi-asserted-by":"crossref","first-page":"14","DOI":"10.7326\/0003-4819-131-1-199907060-00004","article-title":"Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time","volume":"131","author":"Benedetti","year":"1999","journal-title":"Ann. Intern. Med."},{"issue":"23","key":"10.1016\/j.bcp.2022.115322_b0100","first-page":"1444","article-title":"Recurrences after oral and genital herpes simplex virus infection","volume":"316","author":"Lafferty","year":"1987","journal-title":"Influence of site of infection and viral type, N Engl J Med"},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00007435-200302000-00015","article-title":"Natural history of genital herpes simplex virus type 1 infection","volume":"30","author":"Engelberg","year":"2003","journal-title":"Sex. Transm. Dis."},{"issue":"7","key":"10.1016\/j.bcp.2022.115322_b0110","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMcp1603178","article-title":"CLINICAL PRACTICE","volume":"375","author":"Gnann","year":"2016","journal-title":"Genital Herpes, N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2022.115322_b0115","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/jpids\/piu050","article-title":"Mother-to-Child Transmission of Herpes Simplex Virus","volume":"1","author":"James","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0120","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1016\/S2214-109X(16)30362-X","article-title":"First estimates of the global and regional incidence of neonatal herpes infection","volume":"5","author":"Looker","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.17.1.1-13.2004","article-title":"Neonatal herpes simplex infection","volume":"17","author":"Kimberlin","year":"2004","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0130","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.semperi.2018.02.004","article-title":"Neonatal herpes simplex virus infections","volume":"42","author":"Pinninti","year":"2018","journal-title":"Semin. Perinatol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0135","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1542\/peds.66.4.495","article-title":"Vidarabine therapy of neonatal herpes simplex virus infection","volume":"66","author":"Whitley","year":"1980","journal-title":"Pediatrics"},{"key":"10.1016\/j.bcp.2022.115322_b0140","volume":"F1000Res 7","author":"Whitley","year":"2018","journal-title":"Clinical management of herpes simplex virus infections: past, present, and future"},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0145","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/rmv.313","article-title":"Advances in the treatment of neonatal herpes simplex infections","volume":"11","author":"Kimberlin","year":"2001","journal-title":"Rev. Med. Virol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0150","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1542\/peds.108.2.230","article-title":"Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections","volume":"108","author":"Kimberlin","year":"2001","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0155","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/092739490500363","article-title":"Human herpes simplex virus keratitis: the pathogenesis revisited","volume":"12","author":"Remeijer","year":"2004","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0160","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcv.2013.05.001","article-title":"Phenotypic and genotypic characterization of acyclovir-resistant corneal HSV-1 isolates from immunocompetent patients with recurrent herpetic keratitis","volume":"58","author":"Burrel","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.bcp.2022.115322_b0165","first-page":"1","article-title":"Incidence of herpes simplex virus keratitis and other ocular disease: global review and estimates","author":"McCormick","year":"2021","journal-title":"Ophthalmic Epidemiol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115322_b0170","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.survophthal.2012.01.005","article-title":"Herpes simplex epithelial and stromal keratitis: an epidemiologic update","volume":"57","author":"Farooq","year":"2012","journal-title":"Surv. Ophthalmol."},{"issue":"9","key":"10.1016\/j.bcp.2022.115322_b0175","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/infdis\/jit350","article-title":"Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis","volume":"208","author":"van Velzen","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11908-017-0568-7","article-title":"Herpes Simplex Encephalitis: an Update","volume":"19","author":"Gnann","year":"2017","journal-title":"Curr Infect Dis Rep"},{"issue":"7","key":"10.1016\/j.bcp.2022.115322_b0185","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1086\/521262","article-title":"Herpes simplex encephalitis in Sweden, 1990\u20132001: incidence, morbidity, and mortality","volume":"45","author":"Hjalmarsson","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0190","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/jmv.1082","article-title":"Screening for possible failure of herpes simplex virus PCR in cerebrospinal fluid for the diagnosis of herpes simplex encephalitis","volume":"64","author":"Puchhammer-St\u00f6ckl","year":"2001","journal-title":"J. Med. Virol."},{"issue":"12","key":"10.1016\/j.bcp.2022.115322_b0195","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1473-3099(10)70222-X","article-title":"Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study","volume":"10","author":"Granerod","year":"2010","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jcv.2014.03.010","article-title":"Herpes simplex virus encephalitis: clinical manifestations, diagnosis and outcome in 106 adult patients","volume":"60","author":"Sili","year":"2014","journal-title":"J. Clin. Virol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0205","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1017\/S0950268811000483","article-title":"Herpes simplex encephalitis and management of acyclovir in encephalitis patients in France","volume":"140","author":"Stahl","year":"2012","journal-title":"Epidemiol. Infect."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0210","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/v1030979","article-title":"Innate and adaptive immune responses to herpes simplex virus","volume":"1","author":"Chew","year":"2009","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.bcp.2022.115322_b0215","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1200\/JCO.1991.9.10.1903","article-title":"Herpes simplex virus infection in the immunocompromised cancer patient","volume":"9","author":"Bustamante","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0220","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/infdis\/142.3.338","article-title":"Infection with herpes simplex virus and cell-mediated immunity after marrow transplant","volume":"142","author":"Meyers","year":"1980","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0225","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/infdis\/140.4.487","article-title":"Identification of patients with increased risk of infection with herpes simplex virus after renal transplantation","volume":"140","author":"Pass","year":"1979","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.bcp.2022.115322_b0230","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/infdis\/jit019","article-title":"Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy","volume":"207","author":"Andrei","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0235","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/infdis\/162.1.244","article-title":"Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation","volume":"162","author":"Ljungman","year":"1990","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.bcp.2022.115322_b0240","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.bcp.2022.115322_b0245","doi-asserted-by":"crossref","first-page":"8721","DOI":"10.1016\/S0021-9258(17)34236-9","article-title":"Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine","volume":"253","author":"Fyfe","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2022.115322_b0250","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-540-79086-0_3","article-title":"Antiviral agents acting as DNA or RNA chain terminators","volume":"189","author":"De Clercq","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"issue":"15","key":"10.1016\/j.bcp.2022.115322_b0255","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.1016\/S0021-9258(20)79686-9","article-title":"Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase","volume":"255","author":"Miller","year":"1980","journal-title":"J. Biol. Chem."},{"issue":"23","key":"10.1016\/j.bcp.2022.115322_b0260","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1016\/0006-2952(82)90305-7","article-title":"Phosphorylation of acyclovir diphosphate by cellular enzymes","volume":"31","author":"Miller","year":"1982","journal-title":"Biochem. Pharmacol."},{"issue":"13","key":"10.1016\/j.bcp.2022.115322_b0265","first-page":"7405","article-title":"Herpes simplex virus type 1 DNA polymerase","volume":"264","author":"Reardon","year":"1989","journal-title":"Mechanism of inhibition by acyclovir triphosphate, J Biol Chem"},{"issue":"22","key":"10.1016\/j.bcp.2022.115322_b0270","doi-asserted-by":"crossref","first-page":"11447","DOI":"10.1016\/S0021-9258(19)68420-6","article-title":"Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function","volume":"256","author":"Derse","year":"1981","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2022.115322_b0275","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1021\/acs.biochem.6b00065","article-title":"Effects of Acyclovir, Foscarnet, and Ribonucleotides on Herpes Simplex Virus-1 DNA Polymerase: Mechanistic Insights and a Novel Mechanism for Preventing Stable Incorporation of Ribonucleotides into DNA","volume":"55","author":"Vashishtha","year":"2016","journal-title":"Biochemistry"},{"issue":"1 Pt 2","key":"10.1016\/j.bcp.2022.115322_b0280","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0190-9622(88)70022-5","article-title":"History, pharmacokinetics, and pharmacology of acyclovir","volume":"18","author":"King","year":"1988","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.bcp.2022.115322_b0285","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.antiviral.2018.04.004","article-title":"The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold","volume":"154","author":"Seley-Radtke","year":"2018","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0290","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1128\/jvi.32.1.72-77.1979","article-title":"Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate","volume":"32","author":"Furman","year":"1979","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0295","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/095632029200300305","article-title":"Amino acid ester prodrugs of acyclovir","volume":"3","author":"Beauchamp","year":"1992","journal-title":"Antiviral Chem. Chemother."},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0300","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/clpt.1993.196","article-title":"Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers","volume":"54","author":"Weller","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2022.115322_b0305","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1128\/AAC.46.7.2238-2243.2002","article-title":"Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials","volume":"46","author":"Spruance","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2022.115322_b0310","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12886-015-0022-2","article-title":"A systematic review and meta-analysis to compare the efficacy of acyclovir 3% ophthalmic ointment to idoxuridine in curing herpetic keratitis by Day 7 of treatment","volume":"15","author":"Balderson","year":"2015","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0315","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2022.115322_b0320","unstructured":"WHO Guidelines for the Treatment of Genital Herpes Simplex Virus, WHO Guidelines for the Treatment of Genital Herpes Simplex Virus, World Health Organization Copyright \u00a9 World Health Organization 2016., Geneva, 2016."},{"issue":"8","key":"10.1016\/j.bcp.2022.115322_b0325","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1086\/424519","article-title":"Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract","volume":"190","author":"Gupta","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.bcp.2022.115322_b0330","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.olq.0000237853.69443.71","article-title":"A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir","volume":"34","author":"Fife","year":"2007","journal-title":"Sex. Transm. Dis."},{"issue":"30","key":"10.1016\/j.bcp.2022.115322_b0335","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0340","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00277-021-04746-y","volume":"101","author":"Henze","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcp.2022.115322_b0345","doi-asserted-by":"crossref","unstructured":"M. Christopeit, M. Schmidt-Hieber, R. Sprute, D. Buchheidt, M. Hentrich, M. Karthaus, O. Penack, M. Ruhnke, F. Weissinger, O.A. Cornely, G. Maschmeyer, Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO), Ann Hematol 100(2) (2021) 321-336.","DOI":"10.1007\/s00277-020-04297-8"},{"key":"10.1016\/j.bcp.2022.115322_b0350","doi-asserted-by":"crossref","unstructured":"M. Ifversen, R. Meisel, P. Sedlacek, K. Kalwak, L. Sisinni, D. Hutt, T. Lehrnbecher, A. Balduzzi, T. Diesch, A. Jarisch, T. G\u00fcng\u00f6r, J. Stein, I. Yaniv, H. Bonig, M. Kuhlen, M. Ansari, T. Nava, J.H. Dalle, C. Diaz-de-Heredia, E. Trigoso, U. Falkenberg, M. Hartmann, M. Deiana, M. Canesi, C. Broggi, A. Bertaina, B. Gibson, G. Krivan, K. Vettenranta, T. Matic, J. Buechner, A. Lawitschka, C. Peters, A. Yesilipek, K. Yal\u00e7in, G. Lucchini, S. Bakhtiar, D. Turkiewicz, R. Niinim\u00e4ki, J. Wachowiak, S. Cesaro, A. Dalissier, S. Corbacioglu, A.M. Willasch, P. Bader, Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT), Front Pediatr 9 (2021) 705179.","DOI":"10.3389\/fped.2021.705179"},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0355","first-page":"416","article-title":"Herpes simplex virus resistant to acyclovir","volume":"112","author":"Englund","year":"1990","journal-title":"A study in a tertiary care center, Ann Intern Med"},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0360","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-3542(95)00066-6","article-title":"Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy","volume":"28","author":"Beutner","year":"1995","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2022.115322_b0365","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2014.08.013","article-title":"Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France","volume":"111","author":"Frobert","year":"2014","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0370","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jac\/dkv285","article-title":"Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus types 1 and 2","volume":"71","author":"Sauerbrei","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"Pt 12","key":"10.1016\/j.bcp.2022.115322_b0375","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1099\/0022-1317-71-12-2979","article-title":"Herpesviral deoxythymidine kinases contain a site analogous to the phosphoryl-binding arginine-rich region of porcine adenylate kinase; comparison of secondary structure predictions and conservation","volume":"71","author":"Balasubramaniam","year":"1990","journal-title":"J. Gen. Virol."},{"issue":"Pt 9","key":"10.1016\/j.bcp.2022.115322_b0380","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1099\/0022-1317-79-9-2083","article-title":"Herpesviral thymidine kinases: laxity and resistance by design","volume":"79","author":"Evans","year":"1998","journal-title":"J. Gen. Virol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0385","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1099\/0022-1317-24-3-465","article-title":"Induction of both thymidine and deoxycytidine kinase activity by herpes viruses","volume":"24","author":"Jamieson","year":"1974","journal-title":"J. Gen. Virol."},{"issue":"12","key":"10.1016\/j.bcp.2022.115322_b0390","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1073\/pnas.86.12.4736","article-title":"Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate","volume":"86","author":"Coen","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0395","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1128\/jvi.63.6.2861-2865.1989","article-title":"Latency-associated transcript but not reactivatable virus is present in sensory ganglion neurons after inoculation of thymidine kinase-negative mutants of herpes simplex virus type 1","volume":"63","author":"Tenser","year":"1989","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0400","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2010.02.001","article-title":"Human and viral nucleoside\/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties","volume":"86","author":"Deville-Bonne","year":"2010","journal-title":"Antiviral Res."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0405","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0026-895X(25)14611-7","article-title":"Differential phosphorylation of (E)-5-(2-bromovinyl)-2'-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus","volume":"21","author":"Fyfe","year":"1982","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0410","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1368-7646(02)00021-3","article-title":"Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms","volume":"5","author":"Gilbert","year":"2002","journal-title":"Drug Resist Updat"},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0415","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1086\/515626","article-title":"Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients","volume":"178","author":"Gaudreau","year":"1998","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0420","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.antiviral.2012.07.001","article-title":"Effects of mutations on herpes simplex virus 1 thymidine kinase functionality: an in vitro assay based on detection of monophosphate forms of acyclovir and thymidine using HPLC\/DAD","volume":"95","author":"Malartre","year":"2012","journal-title":"Antiviral Res."},{"issue":"11","key":"10.1016\/j.bcp.2022.115322_b0425","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.35.11.2322","article-title":"In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus","volume":"35","author":"Hill","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0430","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/QCO.0000000000000015","article-title":"Herpes simplex virus drug-resistance: new mutations and insights","volume":"26","author":"Andrei","year":"2013","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0435","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1386-6532(02)00263-9","article-title":"Herpes simplex virus resistance to antiviral drugs","volume":"26","author":"Morfin","year":"2003","journal-title":"J. Clin. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0440","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1086\/315696","article-title":"Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients","volume":"182","author":"Morfin","year":"2000","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0445","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.antiviral.2013.09.012","article-title":"Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey","volume":"100","author":"Burrel","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2022.115322_b0450","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev.biochem.66.1.347","article-title":"Herpes simplex virus DNA replication","volume":"66","author":"Boehmer","year":"1997","journal-title":"Annu. Rev. Biochem."},{"issue":"26","key":"10.1016\/j.bcp.2022.115322_b0455","doi-asserted-by":"crossref","first-page":"18193","DOI":"10.1074\/jbc.M602414200","article-title":"Crystal structure of the herpes simplex virus 1 DNA polymerase","volume":"281","author":"Liu","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.bcp.2022.115322_b0460","doi-asserted-by":"crossref","first-page":"11057","DOI":"10.1128\/JVI.01034-12","article-title":"The pre-NH(2)-terminal domain of the herpes simplex virus 1 DNA polymerase catalytic subunit is required for efficient viral replication","volume":"86","author":"Terrell","year":"2012","journal-title":"J. Virol."},{"issue":"Pt 4","key":"10.1016\/j.bcp.2022.115322_b0465","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1099\/vir.0.061903-0","article-title":"Roles of conserved residues within the pre-NH2-terminal domain of herpes simplex virus 1 DNA polymerase in replication and latency in mice","volume":"95","author":"Terrell","year":"2014","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.bcp.2022.115322_b0470","doi-asserted-by":"crossref","first-page":"11767","DOI":"10.1038\/srep11767","article-title":"A Herpesvirus Specific Motif of Epstein-Barr Virus DNA Polymerase Is Required for the Efficient Lytic Genome Synthesis","volume":"5","author":"Narita","year":"2015","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.bcp.2022.115322_b0475","first-page":"9530","article-title":"Distribution and effects of amino acid changes in drug-resistant \u03b1 and \u03b2 herpesviruses DNA polymerase","volume":"44","author":"Topalis","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2022.115322_b0480","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.virusres.2017.01.019","article-title":"Herpesvirus DNA polymerases: Structures, functions and inhibitors","volume":"234","author":"Zarrouk","year":"2017","journal-title":"Virus Res."},{"key":"10.1016\/j.bcp.2022.115322_b0485","first-page":"41","article-title":"Alphaherpesvirus Genomics: Past, Present and Future","volume":"42","author":"Kuny","year":"2021","journal-title":"Curr Issues Mol Biol"},{"issue":"14","key":"10.1016\/j.bcp.2022.115322_b0490","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1128\/JVI.77.14.7820-7829.2003","article-title":"Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids","volume":"77","author":"Bestman-Smith","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2022.115322_b0495","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.antiviral.2019.05.017","article-title":"Added value of ultra-deep sequencing","volume":"168","author":"Mercier-Darty","year":"2019","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0500","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1128\/JCM.39.3.913-917.2001","article-title":"Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates","volume":"39","author":"Shin","year":"2001","journal-title":"J. Clin. Microbiol."},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0505","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1128\/AAC.48.6.2331-2333.2004","article-title":"ELVIRA HSV, a yield reduction assay for rapid herpes simplex virus susceptibility testing","volume":"48","author":"Str\u00e1nsk\u00e1","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0510","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0166-3542(83)90001-3","article-title":"A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents","volume":"3","author":"McLaren","year":"1983","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2022.115322_b0515","first-page":"149","article-title":"Sensitivity of HSV strains isolated before and after treatment with acyclovir","volume":"47","author":"Svennerholm","year":"1985","journal-title":"Scand. J. Infect. Dis. Suppl."},{"issue":"10","key":"10.1016\/j.bcp.2022.115322_b0520","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/AAC.31.10.1465","article-title":"Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus","volume":"31","author":"Swierkosz","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0525","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/CMR.16.1.114-128.2003","article-title":"Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy","volume":"16","author":"Bacon","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0530","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.antiviral.2005.11.004","article-title":"Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR","volume":"69","author":"Thi","year":"2006","journal-title":"Antiviral Res."},{"issue":"9","key":"10.1016\/j.bcp.2022.115322_b0535","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/bjo.74.9.532","article-title":"Antiviral drug sensitivity in ocular herpes simplex virus infection","volume":"74","author":"Menage","year":"1990","journal-title":"Br. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0540","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jcv.2011.06.009","article-title":"Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children","volume":"52","author":"Wang","year":"2011","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.bcp.2022.115322_b0545","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/jmv.1890410512","article-title":"Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir","volume":"1","author":"Collins","year":"1993","journal-title":"J Med Virol Suppl"},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0550","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1128\/AAC.38.6.1246","article-title":"Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients","volume":"38","author":"Safrin","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0555","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/JCM.42.1.242-249.2004","article-title":"Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up","volume":"42","author":"Danve-Szatanek","year":"2004","journal-title":"J. Clin. Microbiol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.1890360102","article-title":"Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: Report on a two\u2014year sensitivity screening survey","volume":"36","author":"Nugier","year":"1992","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0565","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jcv.2004.04.002","article-title":"Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization","volume":"32","author":"Str\u00e1nsk\u00e1","year":"2005","journal-title":"J. Clin. Virol."},{"issue":"9","key":"10.1016\/j.bcp.2022.115322_b0570","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1128\/AAC.46.9.3042-3044.2002","article-title":"Surveillance for antiviral-agent-resistant herpes simplex virus in the general population with recurrent herpes labialis","volume":"46","author":"Bacon","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0575","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/oxfordjournals.jac.a020885","article-title":"Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialis: a UK-based survey","volume":"46","author":"Boon","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0580","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1128\/AAC.42.4.868","article-title":"Survey of resistance of herpes simplex virus to acyclovir in northwest England","volume":"42","author":"Christophers","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0585","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/infdis\/169.6.1338","article-title":"Recurrence and resistance patterns of herpes simplex virus following cessation of \u22656 years of chronic suppression with acyclovir","volume":"169","author":"Fife","year":"1994","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0590","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0163-4453(89)94798-1","article-title":"Susceptibility to acyclovir of herpes simplex virus: emergence of resistance in patients with lymphoid and myeloid neoplasia","volume":"19","author":"Gray","year":"1989","journal-title":"J. Infect."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0595","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/1096-9071(200101)63:1<57::AID-JMV1008>3.0.CO;2-9","article-title":"Susceptibility to acyclovir of herpes simplex virus isolates obtained between 1977 and 1996 in Japan","volume":"63","author":"Hasegawa","year":"2001","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0600","first-page":"141","article-title":"In vitro acyclovir sensitivity of herpes simplex viruses isolated from female genital herpes in Japan, Kansenshogaku zasshi","volume":"62","author":"Hashido","year":"1988","journal-title":"The Journal of the Japanese Association for Infectious Diseases"},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0605","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archinte.163.1.76","article-title":"Task Force Herpes Simplex, Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics","volume":"163","author":"Reyes","year":"2003","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0610","first-page":"908","article-title":"Acyclovir susceptibility of herpes simplex virus isolates at King Chulalongkorn Memorial Hospital","volume":"91","author":"Sangdara","year":"2008","journal-title":"Bangkok, Journal of the Medical Association of Thailand"},{"issue":"8","key":"10.1016\/j.bcp.2022.115322_b0615","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1128\/AAC.00977-15","article-title":"Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance","volume":"59","author":"Schmidt","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0620","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1600-0714.1994.tb00261.x","article-title":"Detection of herpes simplex virus (HSV) in the saliva from 1,000 oral surgery outpatients by the polymerase chain reaction (PCR) and virus isolation","volume":"23","author":"Tateishi","year":"1994","journal-title":"J. Oral Pathol. Med."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0625","first-page":"208","article-title":"Acyclovir susceptibility of herpes simplex virus isolates from transplanted and nontransplanted patients in Rio de Janeiro","volume":"10","author":"Varella","year":"2012","journal-title":"Brazil, Skinmed"},{"issue":"10","key":"10.1016\/j.bcp.2022.115322_b0630","first-page":"572","article-title":"Recovery frequencies of herpes simplex virus types 1 and 2 from symptomatic and asymptomatic genital herpes cases and antiviral sensitivities of isolates, Journal of the Medical Association of Thailand =","volume":"72","author":"Yoosook","year":"1989","journal-title":"Chotmaihet thangphaet"},{"issue":"12","key":"10.1016\/j.bcp.2022.115322_b0635","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1365-4632.2007.03449.x","article-title":"Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome","volume":"46","author":"Ziyaeyan","year":"2007","journal-title":"Int. J. Dermatol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0640","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1086\/514229","article-title":"Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus","volume":"177","author":"Swetter","year":"1998","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0645","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1128\/JCM.44.4.1584-1586.2006","article-title":"Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman","volume":"44","author":"Czartoski","year":"2006","journal-title":"J. Clin. Microbiol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115322_b0650","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1086\/590668","article-title":"Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis","volume":"198","author":"Duan","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.bcp.2022.115322_b0655","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/bjo.74.5.286","article-title":"Ocular herpes simplex virus infections: reduced sensitivity to acyclovir in primary disease","volume":"74","author":"Charles","year":"1990","journal-title":"Br. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115322_b0660","doi-asserted-by":"crossref","first-page":"e0155531","DOI":"10.1371\/journal.pone.0155531","article-title":"Prevalence of Intrathecal Acyclovir Resistant Virus in Herpes Simplex Encephalitis Patients","volume":"11","author":"Mitterreiter","year":"2016","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0665","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcv.2013.10.025","article-title":"Acyclovir-resistant herpes simplex encephalitis in a patient treated with anti-tumor necrosis factor-\u03b1 monoclonal antibodies","volume":"59","author":"Schepers","year":"2014","journal-title":"J. Clin. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0670","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/JCM.02247-12","article-title":"Neonatal herpes encephalitis caused by a virologically confirmed acyclovir-resistant herpes simplex virus 1 strain","volume":"51","author":"Kakiuchi","year":"2013","journal-title":"J. Clin. Microbiol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0675","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1093\/jpids\/pit045","article-title":"Antiviral Drug-Resistance Typing Reveals Compartmentalization and Dynamics of Acyclovir-Resistant Herpes Simplex Virus Type-2 (HSV-2) in a Case of Neonatal Herpes","volume":"3","author":"Bache","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0680","first-page":"266","article-title":"Herpes simplex virus and oral mucositis in children with cancer","volume":"2","author":"Carrega","year":"1994","journal-title":"Support. Care Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0685","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/eri.11.43","article-title":"Management of viral infections in solid organ transplant recipients","volume":"9","author":"Razonable","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"9","key":"10.1016\/j.bcp.2022.115322_b0690","doi-asserted-by":"crossref","first-page":"e13526","DOI":"10.1111\/ctr.13526","article-title":"Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Lee","year":"2019","journal-title":"Clin. Transplant."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0695","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jcv.2004.03.002","article-title":"HSV excretion after bone marrow transplantation: a 4-year survey","volume":"30","author":"Morfin","year":"2004","journal-title":"J. Clin. Virol."},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0700","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/infdis\/148.6.1077","article-title":"Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir","volume":"148","author":"Wade","year":"1983","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0705","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/tri.13142","article-title":"Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study","volume":"31","author":"Ariza-Heredia","year":"2018","journal-title":"Transpl. Int."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0710","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1086\/314052","article-title":"Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation","volume":"31","author":"Chen","year":"2000","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.bcp.2022.115322_b0715","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1159\/000510988","article-title":"Topical treatment of acyclovir-resistant herpes simplex virus stomatitis after allogeneic hematopoietic cell transplantation","volume":"43","author":"Heidenreich","year":"2020","journal-title":"Oncology research and treatment"},{"key":"10.1016\/j.bcp.2022.115322_b0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104421","article-title":"Challenges of aciclovir-resistant HSV infection in allogeneic bone marrow transplant recipients","volume":"128","author":"Anton-Vazquez","year":"2020","journal-title":"J. Clin. Virol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0725","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood.V99.3.1085","article-title":"Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation","volume":"99","author":"Langston","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0730","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","article-title":"Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies","volume":"20","author":"Freeman","year":"2006","journal-title":"Aids"},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0735","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri1058","article-title":"Timeline: AIDS pathogenesis: what have two decades of HIV research taught us?","volume":"3","author":"Rowland-Jones","year":"2003","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.bcp.2022.115322_b0740","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/00002030-199211000-00012","article-title":"Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection","volume":"6","author":"Bagdades","year":"1992","journal-title":"Aids"},{"issue":"23","key":"10.1016\/j.bcp.2022.115322_b0745","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1001\/jama.282.23.2220","article-title":"AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study","volume":"282","author":"Ledergerber","year":"1999","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.bcp.2022.115322_b0750","doi-asserted-by":"crossref","first-page":"845","DOI":"10.7326\/0003-4819-123-11-199512010-00006","article-title":"Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women","volume":"123","author":"Augenbraun","year":"1995","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.bcp.2022.115322_b0755","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00126334-200404150-00001","article-title":"The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics","volume":"35","author":"Corey","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0760","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/infdis\/jix042","article-title":"Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients","volume":"215","author":"Kakiuchi","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.bcp.2022.115322_b0765","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/bmt.2012.2","article-title":"Viral loads and antiviral resistance of herpesviruses and oral ulcerations in hematopoietic stem cell transplant recipients","volume":"47","author":"van der Beek","year":"2012","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0770","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.20011","article-title":"E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU","volume":"25","author":"De Clercq","year":"2005","journal-title":"Med. Res. Rev."},{"issue":"8","key":"10.1016\/j.bcp.2022.115322_b0775","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3851\/IMP1870","article-title":"Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2","volume":"16","author":"Sauerbrei","year":"2011","journal-title":"Antivir Ther"},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0780","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1128\/JVI.75.4.1761-1769.2001","article-title":"Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir","volume":"75","author":"Sarisky","year":"2001","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0785","doi-asserted-by":"crossref","first-page":"e0157600","DOI":"10.1371\/journal.pone.0157600","article-title":"De Novo Assembly of Human Herpes Virus Type 1 (HHV-1) Genome, Mining of Non-Canonical Structures and Detection of Novel Drug-Resistance Mutations Using Short- and Long-Read Next Generation Sequencing Technologies","volume":"11","author":"Karamitros","year":"2016","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0790","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0166-3542(97)00054-5","article-title":"Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants","volume":"37","author":"Pelosi","year":"1998","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.bcp.2022.115322_b0795","first-page":"790","article-title":"The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor","volume":"217","author":"Andrei","year":"2018","journal-title":"Also Targets the Herpes Simplex Virus DNA Polymerase, J Infect Dis"},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0800","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/095632029300401S01","article-title":"Penciclovir: A review of its spectrum of activity, selectivity, and cross-resistance pattern","volume":"4","author":"Boyd","year":"1993","journal-title":"Antiviral Chemistry and Chemotherapy, Supplement"},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0805","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1128\/jvi.66.3.1774-1776.1992","article-title":"A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance","volume":"66","author":"Hwang","year":"1992","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0810","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1167\/iovs.10-5671","article-title":"In vitro synergism of trifluorothymidine and ganciclovir against HSV-1","volume":"52","author":"Hobden","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0815","first-page":"571","article-title":"A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA","volume":"25","author":"Emura","year":"2004","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0820","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3851\/IMP2533","article-title":"Selective anti-herpesvirus agents","volume":"23","author":"De Clercq","year":"2013","journal-title":"Antivir Chem Chemother"},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0825","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00042560-199606010-00007","article-title":"Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172)","volume":"12","author":"Kessler","year":"1996","journal-title":"AIDS Clinical Trials Group, J Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"8826","key":"10.1016\/j.bcp.2022.115322_b0830","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/0140-6736(92)93055-R","article-title":"Topical trifluridine for mucocutaneous acyclovir-resistant herpes simplex II in AIDS patient","volume":"340","author":"Murphy","year":"1992","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0835","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.ico.0000240081.19635.db","article-title":"Dendritic keratitis caused by an acyclovir-resistant herpes simplex virus with frameshift mutation","volume":"26","author":"Zhang","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.bcp.2022.115322_b0840","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-16-0267-2_1","article-title":"Antiviral Drugs Against Herpesviruses","volume":"1322","author":"Piret","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0845","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2174\/1871526519666190617154137","article-title":"Antiviral Drugs and Acute Kidney Injury (AKI)","volume":"19","author":"Leowattana","year":"2019","journal-title":"Infect. Disord. Drug Targets"},{"issue":"9","key":"10.1016\/j.bcp.2022.115322_b0850","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-110-9-710","article-title":"Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS)","volume":"110","author":"Erlich","year":"1989","journal-title":"An uncontrolled trial, Ann Intern Med"},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0855","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1086\/314900","article-title":"Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed","volume":"180","author":"Schmit","year":"1999","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0860","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0026-895X(25)08828-5","article-title":"Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine","volume":"41","author":"Ho","year":"1992","journal-title":"Mol. Pharmacol."},{"issue":"5\u20136","key":"10.1016\/j.bcp.2022.115322_b0865","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0166-3542(87)80004-9","article-title":"Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines","volume":"8","author":"De Clercq","year":"1987","journal-title":"Antiviral Res."},{"issue":"10","key":"10.1016\/j.bcp.2022.115322_b0870","first-page":"1986","article-title":"Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP","volume":"48","author":"Cherrington","year":"1994","journal-title":"AZTTP, and FIAUTP with human DNA polymerases \u03b2 and \u03b3, Biochemical Pharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0875","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/AAC.41.3.594","article-title":"Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation","volume":"41","author":"Xiong","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0880","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/infdis\/171.4.788","article-title":"(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I\/II study of a novel antiviral nucleotide analogue","volume":"171","author":"Lalezari","year":"1995","journal-title":"J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.bcp.2022.115322_b0885","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","article-title":"Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro","volume":"49","author":"Williams-Aziz","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0890","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1097\/MPH.0000000000001227","article-title":"Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD","volume":"40","author":"Detweiler","year":"2018","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"13","key":"10.1016\/j.bcp.2022.115322_b0895","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0900","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0905","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1086\/516542","article-title":"A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS","volume":"176","author":"Lalezari","year":"1997","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0910","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1365-2133.2002.04747.x","article-title":"Successful treatment of an aciclovir-resistant herpes simplex type 2 infection with cidofovir in an AIDS patient","volume":"147","author":"Kopp","year":"2002","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"10.1016\/j.bcp.2022.115322_b0915","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1128\/AAC.39.9.2120","article-title":"Biochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity","volume":"39","author":"Mendel","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.bcp.2022.115322_b0920","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/135965350701200502","article-title":"DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions","volume":"12","author":"Andrei","year":"2007","journal-title":"Antivir Ther"},{"issue":"5","key":"10.1016\/j.bcp.2022.115322_b0925","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/432477","article-title":"Development of herpes simplex virus disease in patients who are receiving cidofovir","volume":"41","author":"Wyles","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b0930","first-page":"1","article-title":"HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues","volume":"8","author":"Naesens","year":"1997","journal-title":"A review of their pharmacology and clinical potential in the treatment of viral infections, Antiviral Chemistry and Chemotherapy"},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0935","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1056\/NEJMoa1410649","article-title":"Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection","volume":"373","author":"Abdool Karim","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2022.115322_b0940","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/infdis\/jiz045","article-title":"Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial","volume":"219","author":"Marrazzo","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b0945","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2022.115322_b0950","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1128\/AAC.00133-12","article-title":"Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor","volume":"56","author":"Katsumata","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0955","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.antiviral.2013.08.024","article-title":"Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir","volume":"100","author":"Field","year":"2013","journal-title":"Antiviral Res."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b0960","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b0965","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jiw129","article-title":"No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy","volume":"214","author":"Edlefsen","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.bcp.2022.115322_b0970","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJMoa1301150","article-title":"Helicase-primase inhibitor pritelivir for HSV-2 infection","volume":"370","author":"Wald","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.bcp.2022.115322_b0975","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.2016.18189","article-title":"Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial","volume":"316","author":"Wald","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.bcp.2022.115322_b0980","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","article-title":"ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2","volume":"65","author":"Chono","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.bcp.2022.115322_b0985","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/1346-8138.15393","article-title":"Pharmaceuticals and Medical Device Agency approval summary: Amenamevir for the treatment of herpes zoster","volume":"47","author":"Shoji","year":"2020","journal-title":"J. Dermatol."},{"issue":"12","key":"10.1016\/j.bcp.2022.115322_b0990","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s12325-017-0642-4","article-title":"Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies","volume":"34","author":"Kusawake","year":"2017","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.bcp.2022.115322_b0995","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/jis019","article-title":"ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study","volume":"205","author":"Tyring","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b1000","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bcp.2012.05.020","article-title":"Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir)","volume":"84","author":"Chono","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2022.115322_b1005","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00705-007-0964-7","article-title":"Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57\u20131293 are associated with increased or decreased virus growth characteristics in tissue culture","volume":"152","author":"Biswas","year":"2007","journal-title":"Arch. Virol."},{"key":"10.1016\/j.bcp.2022.115322_b1010","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkac165","article-title":"Pritelivir for recurrent aciclovir-resistant herpes simplex virus 2 infections in immunocompromised patients","author":"Serris","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.bcp.2022.115322_b1015","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/09564624211006568","article-title":"Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2","volume":"32","author":"Cannon","year":"2021","journal-title":"Int. J. STD AIDS"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2022.115322_b1020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0166-3542(98)00048-5","article-title":"The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process","volume":"40","author":"Pope","year":"1998","journal-title":"Antiviral Res."},{"issue":"23","key":"10.1016\/j.bcp.2022.115322_b1025","doi-asserted-by":"crossref","first-page":"10825","DOI":"10.1073\/pnas.88.23.10825","article-title":"Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex","volume":"88","author":"Katz","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b1030","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1067\/mjd.2001.116215","article-title":"Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial","volume":"45","author":"Sacks","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"10.1016\/j.bcp.2022.115322_b1035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01301-19","article-title":"Activation of 6-Alkoxy-Substituted Methylenecyclopropane Nucleoside Analogs Requires Enzymatic Modification by Adenosine Deaminase-Like Protein 1","volume":"63","author":"Vollmer","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2022.115322_b1040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2015.04.001","article-title":"TAOK3 phosphorylates the methylenecyclopropane nucleoside MBX 2168 to its monophosphate","volume":"119","author":"Komazin-Meredith","year":"2015","journal-title":"Antiviral Res."},{"issue":"8","key":"10.1016\/j.bcp.2022.115322_b1045","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1128\/AAC.00429-13","article-title":"Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses","volume":"57","author":"Prichard","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.bcp.2022.115322_b1050","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/AAC.00976-10","article-title":"Combinatorial approaches to the prevention and treatment of HIV-1 infection","volume":"55","author":"Pirrone","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b1055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2012.12.006","article-title":"Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus","volume":"97","author":"Chono","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2022.115322_b1060","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104754","article-title":"Acyclovir, cidofovir, and amenamevir have additive antiviral effects on herpes simplex virus TYPE 1","volume":"176","author":"Greeley","year":"2020","journal-title":"Antiviral Res."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b1065","first-page":"46","article-title":"New antiviral drugs that target herpesvirus helicase primase enzymes","volume":"10","author":"Kleymann","year":"2003","journal-title":"Herpes"},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b1070","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ana.21979","article-title":"Acyclovir resistance in herpes simplex encephalitis","volume":"67","author":"Schulte","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2022.115322_b1075","first-page":"e47","volume":"117","author":"Gayretli Aydin","year":"2019","journal-title":"Acyclovir Unresponsive Herpes Simplex Encephalitis in a child successfully treated with the addition of Foscarnet"},{"issue":"4","key":"10.1016\/j.bcp.2022.115322_b1080","first-page":"e2467","article-title":"Fulminant Herpes Simplex Virus Type I Encephalitis Despite Maximal Medical Therapy","volume":"10","author":"Katyal","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.bcp.2022.115322_b1085","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkac297","article-title":"Heterogeneity and viral replication fitness of HSV-1 clinical isolates with mutations in the thymidine kinase and DNA polymerase","author":"Schalkwijk","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bcp.2022.115322_b1090","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.antiviral.2019.05.012","article-title":"UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients","volume":"168","author":"Labrunie","year":"2019","journal-title":"Antiviral Res."},{"issue":"8","key":"10.1016\/j.bcp.2022.115322_b1095","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1086\/339490","article-title":"Antiviral susceptibility of herpes simplex viruses and its clinical correlates: A single center's experience","volume":"34","author":"Rabella","year":"2002","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2022.115322_b1100","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/AAC.37.2.357","article-title":"Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis","volume":"37","author":"Boivin","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.bcp.2022.115322_b1105","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1086\/315524","article-title":"Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance","volume":"181","author":"Chakrabarti","year":"2000","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.bcp.2022.115322_b1110","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1086\/367894","article-title":"Transferred herpes simplex virus immunity after stem-cell transplantation: Clinical implications","volume":"187","author":"Nichols","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bcp.2022.115322_b1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105277","article-title":"Phenotypic and genotypic acyclovir resistance surveillance of genital herpes simplex virus 2 in South Africa","volume":"200","author":"Muller","year":"2022","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.bcp.2022.115322_b1120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/ijstd.IJSTD_60_17","article-title":"Isolation, characterization and acyclovir susceptibility of herpes simplex virus isolates among immunocompromised patients","volume":"42","author":"Nag","year":"2021","journal-title":"Indian Journal of Sexually Transmitted Diseases and Aids"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222004166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222004166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:16:51Z","timestamp":1762096611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295222004166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":224,"alternative-id":["S0006295222004166"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115322","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acyclovir resistance in herpes simplex viruses: Prevalence and therapeutic alternatives","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115322"}}